443 related articles for article (PubMed ID: 31779657)
1. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
Giovannini M; Mori F; Barni S; de Martino M; Novembre E
Ital J Pediatr; 2019 Nov; 45(1):151. PubMed ID: 31779657
[TBL] [Abstract][Full Text] [Related]
2. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
3. Biologic agents for severe asthma patients: clinical perspectives and implications.
Caruso M; Morjaria J; Emma R; Amaradio MD; Polosa R
Intern Emerg Med; 2018 Mar; 13(2):155-176. PubMed ID: 29238905
[TBL] [Abstract][Full Text] [Related]
4. Severe asthma: When to resort to biological agents.
Tenero L; Rossignoli S; Piacentini G
Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
[TBL] [Abstract][Full Text] [Related]
5. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
[TBL] [Abstract][Full Text] [Related]
6. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
[TBL] [Abstract][Full Text] [Related]
7. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
[TBL] [Abstract][Full Text] [Related]
8. Biological treatments in childhood asthma.
Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice].
Fomina DS; Mukhina OA; Lebedkina MS; Gadzhieva MK; Bobrikova EN; Sinyavkin DO; Parshin VV; Chernov AA; Belevskiy AS
Ter Arkh; 2022 Mar; 94(3):413-419. PubMed ID: 36286907
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis.
Nachef Z; Krishnan A; Mashtare T; Zhuang T; Mador MJ
J Asthma; 2018 Jan; 55(1):89-100. PubMed ID: 28459601
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab (Nucala°) in asthma.
Prescrire Int; 2017 Feb; 26(179):38-39. PubMed ID: 30726627
[No Abstract] [Full Text] [Related]
13. [SWITCHING BIOLOGICS LED TO GOOD CONTROL IN SEVERE CHILDHOOD ASTHMA: A CASE REPORT].
Imai A; Takizawa T; Sato K; Inoue T; Nishida Y; Yagi H; Arakawa H
Arerugi; 2019; 68(7):869-873. PubMed ID: 31406083
[TBL] [Abstract][Full Text] [Related]
14. [Patients in the IDEAL cohort: A snapshot of severe asthma in France].
Taillé C; Pison C; Nocent C; Devouassoux G; Prud'homme A; Gruber A; Gunsoy N; Albers F
Rev Mal Respir; 2019 Feb; 36(2):179-190. PubMed ID: 30429093
[TBL] [Abstract][Full Text] [Related]
15. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
[TBL] [Abstract][Full Text] [Related]
16. Options of immunotherapeutic treatments for children with asthma.
Porcaro F; Cutrera R; Pajno GB
Expert Rev Respir Med; 2019 Oct; 13(10):937-949. PubMed ID: 31414917
[No Abstract] [Full Text] [Related]
17. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
Huffaker MF; Phipatanakul W
Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
[TBL] [Abstract][Full Text] [Related]
18. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab for asthma in adults and children.
Normansell R; Walker S; Milan SJ; Walters EH; Nair P
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
[TBL] [Abstract][Full Text] [Related]
20. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
Han D; Lee JK
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):742-743. PubMed ID: 30056148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
